BR112018076287A2 - métodos e composições para o tratamento de doença celíaca, sensibilidade ao glúten não celíaca e doença celíaca refratária - Google Patents

métodos e composições para o tratamento de doença celíaca, sensibilidade ao glúten não celíaca e doença celíaca refratária

Info

Publication number
BR112018076287A2
BR112018076287A2 BR112018076287-3A BR112018076287A BR112018076287A2 BR 112018076287 A2 BR112018076287 A2 BR 112018076287A2 BR 112018076287 A BR112018076287 A BR 112018076287A BR 112018076287 A2 BR112018076287 A2 BR 112018076287A2
Authority
BR
Brazil
Prior art keywords
celiac
celiac disease
compositions
treatment
refractory
Prior art date
Application number
BR112018076287-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Leon Francisco
H. TSUJI Wayne
Original Assignee
Amgen Inc.
Celimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc., Celimmune Llc filed Critical Amgen Inc.
Publication of BR112018076287A2 publication Critical patent/BR112018076287A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
BR112018076287-3A 2016-06-15 2016-06-15 métodos e composições para o tratamento de doença celíaca, sensibilidade ao glúten não celíaca e doença celíaca refratária BR112018076287A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/037708 WO2017217985A1 (en) 2016-06-15 2016-06-15 Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease

Publications (1)

Publication Number Publication Date
BR112018076287A2 true BR112018076287A2 (pt) 2019-03-26

Family

ID=56292925

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018076287-3A BR112018076287A2 (pt) 2016-06-15 2016-06-15 métodos e composições para o tratamento de doença celíaca, sensibilidade ao glúten não celíaca e doença celíaca refratária

Country Status (11)

Country Link
EP (1) EP3472202A1 (zh)
JP (2) JP2019521981A (zh)
CN (1) CN109311972A (zh)
AR (1) AR108790A1 (zh)
AU (1) AU2016411388A1 (zh)
BR (1) BR112018076287A2 (zh)
CA (1) CA3020894A1 (zh)
EA (1) EA201892707A1 (zh)
MX (1) MX2018015363A (zh)
TW (2) TW201803591A (zh)
WO (1) WO2017217985A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3558369A4 (en) 2016-12-21 2020-09-09 Cephalon, Inc. ANTIBODIES SPECIFICALLY BINDING TO HUMAN IL-15 AND THEIR USES
JP2022512709A (ja) * 2018-10-31 2022-02-07 ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー 炎症性疾患及び自己免疫疾患を処置する組成物及び方法
IL310275A (en) 2021-08-12 2024-03-01 Amgen Inc Antibody formulations
WO2024028448A1 (en) 2022-08-04 2024-02-08 Calypso Biotech Sa Il-15 inhibitors useful for the treatment of atopic dermatitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
EA015897B1 (ru) * 2003-02-26 2011-12-30 Генмаб А/С Применение человеческого моноклонального антитела к ил-15 в составе композиции и лекарственного препарата (варианты), композиция и лекарственный препарат, его включающие
UA102722C2 (en) * 2009-01-29 2013-08-12 Эббви Инк. Il-1 binding proteins
WO2011031986A1 (en) * 2009-09-10 2011-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health Assays for soluble il-15 receptor alpha
EP2963057A1 (en) * 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15

Also Published As

Publication number Publication date
AU2016411388A1 (en) 2018-11-08
EP3472202A1 (en) 2019-04-24
CN109311972A (zh) 2019-02-05
MX2018015363A (es) 2019-04-15
JP2022001577A (ja) 2022-01-06
TW202327653A (zh) 2023-07-16
EA201892707A1 (ru) 2019-05-31
TW201803591A (zh) 2018-02-01
AR108790A1 (es) 2018-09-26
WO2017217985A1 (en) 2017-12-21
CA3020894A1 (en) 2017-12-21
JP2019521981A (ja) 2019-08-08

Similar Documents

Publication Publication Date Title
CY1123845T1 (el) Τοπικα φαρμακευτικα σκευασματα για την αγωγη φλεγμονωδων καταστασεων
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1123361T1 (el) Παραγωγο ισοϊνδολινης, ενδιαμεσο, μεθοδος παρασκευης, φαρμακευτικη συνθεση και χρηση αυτου
CY1122184T1 (el) Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη
CY1121473T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
MD3360559T2 (ro) Compoziții conținând tulpini bacteriene
MD3204024T2 (ro) Compoziții care conțin tulpini bacteriene
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
MD3240554T2 (ro) Blautia stercosis și wexlerae pentru utilizare în tratarea bolilor inflamatorii și autoimune
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
BR112016018408A2 (pt) moléculas de anticorpo à lag-3 e usos das mesmas
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
DK3542635T3 (da) Valleproteinbaseret yoghurtlignende produkt med højt proteinindhold, ingrediens egnet til fremstilling deraf og fremgangsmåde til fremstilling.
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
SA518391831B1 (ar) تركيبات وطرق لخفض تعبير البروتين تاو
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
BR112018076287A2 (pt) métodos e composições para o tratamento de doença celíaca, sensibilidade ao glúten não celíaca e doença celíaca refratária
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201791845A1 (ru) Твердые формы менахинолов
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]